ClinicalTrials.Veeva

Menu
A

Allergy Asthma Research Institute | Waco, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

azelastine hydrochloride
BLU-5937
fluticasone propionate
Fluticasone Propionate
Lebrikizumab
Diphenhydramine
Azelastine Hydrochloride
azelastine Hcl
Symbicort®
S-600918

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 21 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The stu...

Enrolling
Perennial Allergic Rhinitis (PAR)
Drug: Placebo
Drug: LY3650150

Trial sponsors

Meda Pharmaceuticals logo
B
N
Sumitomo Pharma logo
Allergy Therapeutics logo
B
F
Johnson & Johnson (J&J) logo
K
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems